{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:59:09Z","timestamp":1794344349856,"version":"4.9.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-95978-9","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T18:42:21Z","timestamp":1743792141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Tolerability of different doses of oliceridine versus traditional opioids in acute pain management: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Yulin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"1","key":"95978_CR1","first-page":"63","volume":"104","author":"O Amaechi","year":"2021","unstructured":"Amaechi, O., Huffman, M. M. & Featherstone, K. Pharmacologic therapy for acute pain. Am. Fam. Physician. 104(1), 63\u201372 (2021).","journal-title":"Am. Fam. Physician."},{"issue":"2","key":"95978_CR2","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s40122-021-00299-0","volume":"10","author":"GB Hammer","year":"2021","unstructured":"Hammer, G. B. et al. Oliceridine exhibits improved tolerability compared to morphine at equianalgesic conditions: Exploratory analysis from two phase 3 randomized placebo and active controlled trials. Pain Ther. 10(2), 1343\u20131353. https:\/\/doi.org\/10.1007\/s40122-021-00299-0 (2021).","journal-title":"Pain Ther."},{"issue":"7","key":"95978_CR3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/emermed-2022-212869","volume":"40","author":"I Qureshi","year":"2023","unstructured":"Qureshi, I. et al. Comparison of intravenous paracetamol (acetaminophen) to intravenously or intramuscularly administered non-steroidal anti-inflammatory drugs (NSAIDs) or opioids for patients presenting with moderate to severe acute pain conditions to the ED: Systematic review and meta-analysis. Emerg. Med. J. 40(7), 499\u2013508 (2023).","journal-title":"Emerg. Med. J."},{"issue":"1","key":"95978_CR4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40122-020-00216-x","volume":"10","author":"TL Beard","year":"2021","unstructured":"Beard, T. L. et al. Oliceridine is associated with reduced risk of vomiting and need for rescue antiemetics compared to morphine: Exploratory analysis from two phase 3 randomized placebo and active controlled trials. Pain Ther. 10(1), 401\u2013413 (2021).","journal-title":"Pain Ther."},{"key":"95978_CR5","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108312","volume":"241","author":"Y Noufal","year":"2023","unstructured":"Noufal, Y., Kringel, D., Toennes, S. W., Dudziak, R. & L\u00f6tsch, J. Pharmacological data science perspective on fatal incidents of morphine treatment. Pharmacol. Ther. 241, 108312 (2023).","journal-title":"Pharmacol. Ther."},{"issue":"10","key":"95978_CR6","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1177\/1060028020987679","volume":"55","author":"Y Liu","year":"2021","unstructured":"Liu, Y., Hu, Q. & Yang, J. Oliceridine for the management of acute postoperative pain. Ann. Pharmacother. 55(10), 1283\u20131289 (2021).","journal-title":"Ann. Pharmacother."},{"issue":"16","key":"95978_CR7","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s40265-020-01414-9","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham, A. Oliceridine: First approval [published correction appears in drugs. Drugs 80(16), 1739\u20131744 (2020).","journal-title":"Drugs"},{"issue":"1","key":"95978_CR8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/j.pain.0000000000000363","volume":"157","author":"ER Viscusi","year":"2016","unstructured":"Viscusi, E. R. et al. A randomized, phase 2 study investigating TRV130, a biased ligand of the \u03bc-opioid receptor, for the intravenous treatment of acute pain. Pain 157(1), 264\u2013272 (2016).","journal-title":"Pain"},{"key":"95978_CR9","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/JPR.S137952","volume":"10","author":"N Singla","year":"2017","unstructured":"Singla, N. et al. A randomized, Phase IIb study investigating oliceridine (TRV130), a novel \u00b5-receptor G-protein pathway selective (\u03bc-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. J. Pain Res. 10, 2413\u20132424 (2017).","journal-title":"J. Pain Res."},{"issue":"2","key":"95978_CR10","volume":"19","author":"A Wolf","year":"2024","unstructured":"Wolf, A., Unterberg, M., Witowski, A., Adamzik, M. & Wolf, A. Efficacy, safety, and side effects of oliceridine in acute postoperative pain, a protocol for a systematic review and meta-analysis. PLoS ONE 19(2), e0299320 (2024).","journal-title":"PLoS ONE"},{"issue":"11","key":"95978_CR11","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/14740338.2021.1965989","volume":"20","author":"HS Tan","year":"2021","unstructured":"Tan, H. S. & Habib, A. S. Safety evaluation of oliceridine for the management of postoperative moderate-to-severe acute pain. Expert Opin. Drug Saf. 20(11), 1291\u20131298 (2021).","journal-title":"Expert Opin. Drug Saf."},{"key":"95978_CR12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/JPR.S171013","volume":"12","author":"ER Viscusi","year":"2019","unstructured":"Viscusi, E. R. et al. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the \u00b5-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J. Pain Res. 12, 927\u2013943 (2019).","journal-title":"J. Pain Res."},{"issue":"7","key":"95978_CR13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/papr.12801","volume":"19","author":"NK Singla","year":"2019","unstructured":"Singla, N. K. et al. APOLLO-2: A randomized, placebo and active-controlled phase iii study investigating oliceridine (TRV130), a G protein-biased ligand at the \u03bc-opioid receptor, for management of moderate to severe acute pain following abdominoplasty. Pain Pract. 19(7), 715\u2013731 (2019).","journal-title":"Pain Pract."},{"key":"95978_CR14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2147\/DDDT.S372612","volume":"17","author":"N Daksla","year":"2023","unstructured":"Daksla, N., Wang, A., Jin, Z., Gupta, A. & Bergese, S. D. Oliceridine for the management of moderate to severe acute postoperative pain: A narrative review. Drug Des. Devel. Ther. 17, 875\u2013886 (2023).","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"95978_CR15","doi-asserted-by":"crossref","first-page":"e230041","DOI":"10.57264\/cer-2023-0041","volume":"13","author":"J Biskupiak","year":"2024","unstructured":"Biskupiak, J., Oderda, G., Brixner, D. & Wandstrat, T. L. Gastrointestinal adverse effects associated with the use of intravenous oliceridine compared with intravenous hydromorphone or fentanyl in acute pain management utilizing adjusted indirect treatment comparison methods. J. Comp. Eff. Res. 13(5), e230041 (2024).","journal-title":"J. Comp. Eff. Res."},{"issue":"2","key":"95978_CR16","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s40122-021-00313-5","volume":"10","author":"AD Kaye","year":"2021","unstructured":"Kaye, A. D. et al. Pharmacological advances in opioid therapy: A review of the role of oliceridine in pain management. Pain Ther. 10(2), 1003\u20131012 (2021).","journal-title":"Pain Ther."},{"issue":"1","key":"95978_CR17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14656566.2021.1982893","volume":"23","author":"Z Jin","year":"2022","unstructured":"Jin, Z. et al. Evaluating oliceridine as a treatment option for moderate to severe acute post-operative pain in adults. Expert Opin. Pharmacother. 23(1), 9\u201317 (2022).","journal-title":"Expert Opin. Pharmacother."},{"issue":"1","key":"95978_CR18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/ph17010029","volume":"17","author":"A Wang","year":"2023","unstructured":"Wang, A. et al. Novel opioids in the setting of acute postoperative pain: A narrative review. Pharmaceuticals 17(1), 29 (2023).","journal-title":"Pharmaceuticals"},{"issue":"6","key":"95978_CR19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/ACO.0000000000001063","volume":"34","author":"N Rajan","year":"2021","unstructured":"Rajan, N. & Joshi, G. P. Management of postoperative nausea and vomiting in adults: Current controversies. Curr. Opin. Anaesthesiol. 34(6), 695\u2013702 (2021).","journal-title":"Curr. Opin. Anaesthesiol."},{"issue":"1","key":"95978_CR20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/ACO.0000000000001220","volume":"36","author":"T Schlesinger","year":"2023","unstructured":"Schlesinger, T., Meybohm, P. & Kranke, P. Postoperative nausea and vomiting: risk factors, prediction tools, and algorithms. Curr. Opin. Anaesthesiol. 36(1), 117\u2013123 (2023).","journal-title":"Curr. Opin. Anaesthesiol."},{"issue":"9","key":"95978_CR21","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.pain.2014.06.011","volume":"155","author":"DG Soergel","year":"2014","unstructured":"Soergel, D. G. et al. Biased agonism of the \u03bc-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain 155(9), 1829\u20131835 (2014).","journal-title":"Pain"},{"issue":"10343","key":"95978_CR22","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(22)00582-7","volume":"399","author":"JF Fiore Jr","year":"2022","unstructured":"Fiore, J. F. Jr. et al. Opioid versus opioid-free analgesia after surgical discharge: A systematic review and meta-analysis of randomised trials. Lancet 399(10343), 2280\u20132293 (2022).","journal-title":"Lancet"},{"issue":"1","key":"95978_CR23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/pmt.15.49","volume":"6","author":"ER Viscusi","year":"2016","unstructured":"Viscusi, E. R. et al. A comparison of opioid-related adverse events with fentanyl iontophoretic transdermal system versus morphine intravenous patient-controlled analgesia in acute postoperative pain. Pain Manag. 6(1), 19\u201324 (2016).","journal-title":"Pain Manag."},{"issue":"5","key":"95978_CR24","first-page":"537","volume":"77","author":"Q Song","year":"2023","unstructured":"Song, Q., Pan, Y., Kanazawa, T. & Morimatsu, H. Relationship of intraoperative SpO2 and ETCO2 values with postoperative hypoxemia in elderly patients after non-cardiac surgery. Acta Med. Okayama. 77(5), 537\u2013543 (2023).","journal-title":"Acta Med. Okayama."},{"issue":"3","key":"95978_CR25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/jpm14030276","volume":"14","author":"M Lee","year":"2024","unstructured":"Lee, M., Lee, C., Choi, G. J. & Kang, H. Remimazolam for procedural sedation in older patients: A systematic review and meta-analysis with trial sequential analysis. J Pers Med. 14(3), 276 (2024).","journal-title":"J Pers Med."},{"issue":"12","key":"95978_CR26","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/j.hrthm.2021.08.028","volume":"18","author":"A Burashnikov","year":"2021","unstructured":"Burashnikov, A. et al. Intracellular uptake of agents that block the hERG channel can confound the assessment of QT interval prolongation and arrhythmic risk. Heart Rhythm 18(12), 2177\u20132186. https:\/\/doi.org\/10.1016\/j.hrthm.2021.08.028 (2021).","journal-title":"Heart Rhythm"},{"issue":"5","key":"95978_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.tcm.2023.03.006","volume":"34","author":"A El Sherbini","year":"2024","unstructured":"El Sherbini, A. et al. Opioids-induced inhibition of HERG ion channels and sudden cardiac death, a systematic review of current literature. Trends Cardiovasc. Med. 34(5), 279\u2013285. https:\/\/doi.org\/10.1016\/j.tcm.2023.03.006 (2024).","journal-title":"Trends Cardiovasc. Med."},{"key":"95978_CR28","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int. J. Surg. 88, 105906 (2021).","journal-title":"Int. J. Surg."},{"key":"95978_CR29","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea, B. J. et al. AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Br. Med. J. 358, j4008 (2017).","journal-title":"Br. Med. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95978-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95978-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95978-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T18:42:59Z","timestamp":1743792179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95978-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95978"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95978-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11470"}}